RxSight offers strong growth potential in cataract treatment, with scalable tech, a large market, and attractive valuation.

Explore Frontline's Q1 2025 performance, trading insights linked to Brent oil prices, and valuation analysis. Read more on ...

Things have been good for stocks over the last two months. Maybe too good, according to a new report from Bank of America.

A frothy market describes a period where asset prices are rising rapidly and are seen as being detached from their true, ...

Jeff Clark on How to Profit From Market Volatility There’s a key signal tracked by the Federal Reserve – one that has correctly foreshadowed every U.S. recession since 1969. It triggered a few years ...

By the closing bell, the blue-chip Dow Jones Industrial Average was up 1.1% at 42,762, the broad-based S&P 500 had added 1.0% ...

The U.S. stock rebound has driven key indexes to the cusp of record levels, with fresh economic data and trade and fiscal ...

The New York-based company's stock touched as much as $117.45, more than triple its offer price of $31 and valuing the ...

In this podcast, Motley Fool analysts Andy Cross and Asit Sharma discuss May's market bounce, plus earnings from ZScaler and Ulta Beauty. To catch full episodes of all The Motley Fool's free podcasts, ...

Retail investors seem to have spotted an opportunity in the sudden feud between U.S. President Donald Trump and his former ...

Virtuals Protocol's price edges higher, more than 12% on Friday, while trading at around $1.85 at the time of writing. The AI token, valued at $1.2 billion, holds above short-term support provided by ...

For now, he is recommending high-quality, short-duration bond ETFs and funds. "These instruments offer a more attractive risk/return profile in the current environment and are less sensitive to ...